The ALS Association awarded $400,000 to University of Missouri-Columbia School of Medicine and its NextGen Precision Health Initiative as part of its program to encourage more amyotrophic lateral sclerosis (ALS) patients living in rural areas to take part in clinical trials. The university’s 2023 Trial Capacity Award…
ALS Association supports work to bring rural patients into clinical trials
One of my duties as a moderator for the ALS News Today Forums is to encourage new members to discuss their worries about living with the disease. I often find myself repeating the same advice over and over: that they be open to changing their perspective, that they…
AcuraStem has secured nearly $7 million in grant funding from the National Institutes of Health (NIH) and the Department of Defense (DOD) to accelerate the development of therapies for amyotrophic lateral sclerosis (ALS) and related diseases. Coming on the heels of a…
Cigarette smoking, either currently or in the past, significantly increases the likelihood of developing amyotrophic lateral sclerosis (ALS), particularly for women, according to a pooled meta-analysis of 32 studies. A risk of the neurodegenerative condition was higher in current smokers, and it increased in a non-linear manner with more…
I have always been a summer person, relishing how everything in nature quietly comes to life — lush, green grass, abundant wildlife, and densely leafy trees. To me, summer evokes peace, calm, and lazier days. My late husband, Jeff, on the other hand, was a winter person. As much as…
The ALS Society of Canada (ALS Canada) has awarded two expedited grants totaling $200,000 to international researchers seeking to advance understanding of amyotrophic lateral sclerosis (ALS). Provided through the 2023 ALS Canada Acceleration Grant Program, a $100,000 grant will support Mónica Povedano, MD, at the Hospital de Bellvitge-IDIBELL…
My husband, Todd, is homebound due to ALS and I am his primary caregiver. That often makes our lives feel small. While I appreciate the small joys of life at home — watching birds perch in the tree outside my kitchen window, enjoying a cup of loose-leaf tea,…
Reduced activity of the TDP-43 protein, a hallmark of amyotrophic lateral sclerosis (ALS), leads to changes in the DNA of nerve cells, which alters the activity of important genes, a new study reports. These findings may help explain how problems with this protein can contribute to the death of…
A European Medicines Agency (EMA) committee again has delayed issuing an opinion on whether to grant conditional approval to masitinib, a potential add-on oral therapy for amyotrophic lateral sclerosis (ALS). AB Science, the therapy’s developer, now expects a recommendation in the second quarter of this year. The…
An early-stage clinical trial evaluating CK0803, Cellenkos‘ regulatory T-cell-based therapy for people with amyotrophic lateral sclerosis (ALS), has completed dosing its first patient group, the company announced in a press release. The six patients, all adults, were treated at the Columbia University Irving Medical Center, in New…
Recent Posts
- Scientists find promising 3 drug combo for sporadic ALS using new models
- Small adjustments to a wheelchair can greatly improve comfort
- How ALS patients can show their stripes for Rare Disease Month
- Grants support next generation of ALS researchers in Canada
- ALS research wins big bucks with $313M in new US government funding